MRA on GMP Inspections between Switzerland and Canada extended
Recommendation
27/28 May 2026
Batch Manufacturing Documents: from Preparation to Operational Excellence
On the Road to 30,000 Members
Let us become the World's Leading GMP/GDP Compliance Community in 2026
The Mutual Recognition Agreement (MRA on Medicinal Products: Drug GMP Compliance Certification, Sectoral Annex on GMP) between Switzerland and Canada on the GMP certification of medicinal products has been in force since 2000. The text has not been revised since then.
However, Health Canada and Swissmedic have now agreed to extend the existing approach of recognising GMP inspection results to include inspections carried out in countries outside the territories of the respective contracting parties. In addition, "stable" medicinal products derived from human blood or human plasma will be included. In addition, it was agreed to introduce processes for the exchange of information and compliance for product-specific on-site evaluations (OSE) by Health Canada and pre-approval inspections by Swissmedic.
Source: Swissmedic
Related GMP News
22.04.2026No Validation, No Controls, and No Suitable Rooms and Equipment - Extensive Warning Letter
25.03.2026FDA Warning Letter highlights once again: Weaknesses in the CAPA Process remain a key GMP Issue
18.03.2026FDA Issues Draft Guidance on Responding to Form 483 Observations
28.01.2026What is the Procedure for GMP Inspections (EU GMP inspections and FDA Inspections)?
21.01.2026FDA Warning Letter highlights critical Failures in Supplier and Quality Oversight
19.01.2026GMP Auditor Association Developments September through December 2025